- PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer.
- The study met its primary endpoints demonstrating equivalence and non-inferiority to the reference product.
- Data presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition.
Holzkirchen, 7 December 2015 – Sandoz, a Novartis company and global leader in biosimilars, today announced results from the PROTECT 2 study which compared the …